The post examines the collaboration between Gilead, IPA, and Natco Pharma regarding the sofosbuvir patent in India. It analyses how voluntary licensing and innovative policies are improving access to affordable medicines while balancing public health and patent rights.
Read more about Gilead, IPA, Natco & The Bells of HarmonyTag: sofosbuvir
‘Killead’s Patent Application Killed by the Indian Patent Office!
Gilead’s patent for Sofosbuvir was rejected by the Indian Patent Office on grounds of insufficient therapeutic efficacy. This landmark decision enables wider access to affordable generic Hepatitis C treatments in India.
Read more about ‘Killead’s Patent Application Killed by the Indian Patent Office!